Mandashi

Mandashi is a venture capital investment firm established in 2021 and located in Sheffield, United Kingdom. The firm focuses on investing in early-stage startups that demonstrate innovation and the potential to make a positive impact on society. By supporting businesses that aim to drive meaningful change, Mandashi seeks to foster growth in sectors that contribute positively to the world.

Danny Evans

Investment Manager

Andrew Evans Ph.D

Co-Founder and Director

8 past transactions

FourJaw Manufacturing Analytics

Seed Round in 2023
FourJaw Manufacturing Analytics is a provider of a machine-agnostic data analytics platform designed to enhance machining productivity through real-time insights into factory operations. The platform offers a comprehensive view of the shop floor, allowing users to monitor and record the status of each machine, thereby identifying and addressing unplanned downtime effectively. By delivering cloud-based machine monitoring, FourJaw enables small and medium-sized enterprise manufacturers to access critical manufacturing analytics, ultimately promoting improved productivity and operational efficiency.

Hero of Health

Seed Round in 2023
Hero of Health is an online platform that empowers individuals with chronic illnesses to manage their health digitally. It promotes healthy aging by offering personalized lifestyle habit plans, healthy aging recipes, and meal plans, aiming to reverse chronic illnesses and enable users to live healthier, more enjoyable lives.

GitLife Biotech

Pre Seed Round in 2023
GitLife Biotech is a biotechnology company that focuses on providing a structured and centralized platform for synthetic biology. It offers a range of DNA-based biosecurity tools that embed proof of ownership directly within the DNA of biological assets. This innovative approach allows scientists to protect their developments without the need for traditional patenting, as the DNA sequence serves as a means of establishing ownership. By facilitating reproducibility and ownership verification, GitLife Biotech aims to support the scaling of synthetic biology, making it easier for researchers to secure their innovations and intellectual property in a rapidly advancing field.

Ferrio

Seed Round in 2022
Ferrio is a business automation services company that specializes in developing a platform aimed at streamlining data automation and integration processes. The company's offerings focus on automating sales processes, allowing users to efficiently gather data from suppliers without direct communication. Additionally, Ferrio's platform manages application programming interface connections to ensure they remain current, thereby facilitating smoother operations. By eliminating time-consuming and error-prone tasks, Ferrio enables businesses to concentrate on activities that promote growth and enhance resource utilization.

Wild Hydrogen

Seed Round in 2022
Wild Hydrogen specializes in innovative technology that converts unprocessed biomass into hydrogen and carbon dioxide under pressure. The company aims to decrease reliance on fossil fuels and stabilize energy grids by developing systems that utilize organic waste to produce clean energy. This process not only generates hydrogen as a fuel source but also actively removes carbon from the atmosphere, offering a sustainable solution for clients seeking affordable hydrogen with negative carbon emissions during production and zero emissions during usage. Through its advancements, Wild Hydrogen contributes to environmental sustainability and the transition to cleaner energy alternatives.

Superbio.ai

Seed Round in 2021
Superbio.ai is a software-based data science and machine learning agency.

RareCan

Seed Round in 2021
RareCan is an organization focused on accelerating research and improving outcomes for individuals with rare forms of cancer. It has developed a direct-to-patient clinical trial platform that enhances the efficiency and cost-effectiveness of accessing patients and data necessary for precision medicine trials. This platform employs innovative technology to create novel pipelines that facilitate the rapid delivery of new treatments. By streamlining the clinical trial process, RareCan aims to support researchers in discovering more effective therapies for cancer, thereby increasing the success rates of trials targeting rare cancers and contributing to advancements in the global cancer drug market.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.